成大生物：人用二倍体狂犬疫苗获药品注册证书

Core Viewpoint - Chengda Biological (688739.SH) announced that its wholly-owned subsidiary, Chengda Biological (Benxi) Co., Ltd., has recently received the Drug Registration Certificate for the lyophilized human rabies vaccine (human diploid cells) from the National Medical Products Administration [1] Group 1 - The company has successfully obtained regulatory approval for its human diploid rabies vaccine, which is a significant milestone in its product development [1] - The approval indicates the company's commitment to expanding its vaccine portfolio and enhancing its market presence in the biopharmaceutical industry [1]